<?xml version="1.0" encoding="UTF-8"?>
<p id="Par11">The primary objectives were to determine the MTD of IMGN529 administered as a single agent once every three weeks to patients with relapsed or refractory NHL, as well as the recommended dose for further phase 2 studies. Secondary objectives were assessments of safety, tolerability, pharmacokinetics, and preliminary evidence of clinical activity according to standard response criteria. Potential predictive biomarkers for efficacy were evaluated as an exploratory objective.</p>
